Abatacept therefore inhibits circulating and synovial T cell activation by inhibiting CTLA-4:CD28 interactions, and has shown remarkable efficacy in disease management (26), reducing progression of undifferentiated arthritis to RA, and reduction of radiological progression and levels of anti-CCP antibodies (27). This evidence concerns the gene CTLA4 and rheumatoid arthritis.